Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

TF, Cloughesy; J, Landolfi; DJ, Hogan; S, Bloomfield; B, Carter; CC, Chen; JB, Elder; SN, Kalkanis; S, Kesari; A, Lai; IY, Lee; LM, Liau; T, Mikkelsen; PL, Nghiemphu; D, Piccioni; T, Walbert; A, Chu; A, Das; OR, Diago; D, Gammon; HE, Gruber; M, Hanna; DJ, Jolly; N, Kasahara; D, McCarthy; L, Mitchell; D, Ostertag; JM, Robbins; M, Rodriguez-Aguirre; MA, Vogelbaum

doi:10.1126/scitranslmed.aad9784

Public

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.

Shared by NobleBlocks on Jun 1, 2016 • 12:00 AM UTC

Authors:

Cloughesy TF

Landolfi J

Hogan DJ

Abstract

Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently administered courses of the investigational prodrug Toca FC (extended-release 5-fluorocytosine) into the antimetabolite 5-flu...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!